Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | mitogen activated protein kinase | 0.0119 | 0.5 | 0.5 |
Giardia lamblia | Kinase, CMGC MAPK | 0.0119 | 0.5 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0119 | 0.5 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.0119 | 0.5 | 0.5 |
Trypanosoma brucei | protein kinase, putative | 0.0119 | 0.5 | 0.5 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.0119 | 0.5 | 0.5 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.0119 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0119 | 0.5 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0119 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0119 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0119 | 0.5 | 0.5 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.0119 | 0.5 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.0119 | 0.5 | 0.5 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.0119 | 0.5 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.0119 | 0.5 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0119 | 0.5 | 0.5 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.0119 | 0.5 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.0119 | 0.5 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase | 0.0119 | 0.5 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0119 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | > 100 uM | Inhibitory activity against human cytomegalovirus determined by plaque reduction assay | ChEMBL. | 2840500 |
IC50 (functional) | > 100 uM | Antiviral activity against Herpes simplex virus type 1 determined by plaque reduction assay | ChEMBL. | 2840500 |
IC50 (functional) | > 100 uM | The compound was tested for cytotoxicity against human foreskin fibroblast cell | ChEMBL. | 2840500 |
IC50 (functional) | > 100 uM | The compound was tested for cytotoxicity against BSC1 cell | ChEMBL. | 2840500 |
IC50 (functional) | > 100 uM | The compound was tested for cytotoxicity against human foreskin fibroblast cell | ChEMBL. | 2840500 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.